On Monday, Johnson & Johnson (NYSE: JNJ ) received approval in Europe for Zytiga as a pre-chemo treatment for prostate cancer. With Dendreon's (Nasdaq: DNDN ) drug Provenge not approved in Europe yet, should investors be concerned about its ability to gain traction on the continent? Watch the following video and find out.
Dendreon's run over the past four years saw sub-$5 share prices skyrocket to 10-bagger status before tumbling all the way back down below $5, as its revolutionary prostate cancer vaccine Provenge became a lightning rod of debate. But where does that leave investors -- other than a bit nauseated from the roller-coaster ride? Our own David Williamson answers this question, and many more, inside our brand new premium research report on Dendreon. Inside, he details every key issue facing the company and outlines just how Dendreon intends to regain its former glory. The report also comes with a full year of analyst updates, so claim your copy of this exclusive report today by clicking here now.